ReviewDiabetes, obesity & metabolism2020

Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.

Jinnie J Rhee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.